Evidence map›Paper›PMID 42698021›Full record

ArticleEMBO reports2026

Vimentin loss inhibits DNA damage responses and promotes cancer cell survival.

Elvira Infante, Emmanuel Terriac, Matthieu Gelin, Vanessa Roca, Saline Jabre, Hugo Siegfried, David Pereira, Hugo Varet, Sara Khalilian, Atef Asnacios and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Elvira InfanteCell Polarity, Migration and Cancer Unit, Institut Pasteur, UMR3691 CNRS, Université Paris-Cité, Equipe Labellisée Ligue Contre le Cancer 2023, F-75015, Paris, France. elvira.infante@kcl.ac.uk.ORCID http://orcid.org/0000-0002-9883-8391
Emmanuel TerriacCell Polarity, Migration and Cancer Unit, Institut Pasteur, UMR3691 CNRS, Université Paris-Cité, Equipe Labellisée Ligue Contre le Cancer 2023, F-75015, Paris, France.ORCID http://orcid.org/0000-0002-8769-242X
Matthieu GelinCell Polarity, Migration and Cancer Unit, Institut Pasteur, UMR3691 CNRS, Université Paris-Cité, Equipe Labellisée Ligue Contre le Cancer 2023, F-75015, Paris, France.
Vanessa RocaCell Polarity, Migration and Cancer Unit, Institut Pasteur, UMR3691 CNRS, Université Paris-Cité, Equipe Labellisée Ligue Contre le Cancer 2023, F-75015, Paris, France.ORCID http://orcid.org/0009-0000-6048-7883
Saline JabreCell Polarity, Migration and Cancer Unit, Institut Pasteur, UMR3691 CNRS, Université Paris-Cité, Equipe Labellisée Ligue Contre le Cancer 2023, F-75015, Paris, France.
Hugo SiegfriedCell Polarity, Migration and Cancer Unit, Institut Pasteur, UMR3691 CNRS, Université Paris-Cité, Equipe Labellisée Ligue Contre le Cancer 2023, F-75015, Paris, France.ORCID http://orcid.org/0000-0002-1785-9589
David PereiraMatières et Systèmes Complexes, Université Paris-Cité, CNRS, F-75013, Paris, France.ORCID http://orcid.org/0000-0003-3811-8349
Hugo VaretBioinformatics and Biostatistics Hub, Institut Pasteur, Université Paris-Cité, F-75015, Paris, France.ORCID http://orcid.org/0000-0003-3980-4463
Sara KhalilianCell Polarity, Migration and Cancer Unit, Institut Pasteur, UMR3691 CNRS, Université Paris-Cité, Equipe Labellisée Ligue Contre le Cancer 2023, F-75015, Paris, France.
Atef AsnaciosMatières et Systèmes Complexes, Université Paris-Cité, CNRS, F-75013, Paris, France.ORCID http://orcid.org/0000-0002-3146-476X
Emma J van BodegravenDepartment of Translational Neuroscience, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, 3584 CG, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-3796-2516
Sandrine Etienne-MannevilleCell Polarity, Migration and Cancer Unit, Institut Pasteur, UMR3691 CNRS, Université Paris-Cité, Equipe Labellisée Ligue Contre le Cancer 2023, F-75015, Paris, France. setienne@pasteur.fr.ORCID http://orcid.org/0000-0001-6651-3675

Funding

Fondation de France (Fondationfrance) WB-2021-35925INCA PCSI N{degree sign} 22CP073-00INCA PLBIO PLBIO24-072Institut Pasteur (Pasteur Institute) PTR-548-22La Ligue contre le cancer EL2023 - DN/IP/IQ - 17691Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) VI.Veni.212.117Worldwide Cancer Research (WCR) WCR 23-0156
6 · The paper itself

Abstract

Vimentin intermediate filaments are a hallmark of aggressive tumours and are widely linked to invasion and EMT, yet how vimentin-dependent mechanics shape genome maintenance and therapy response is unclear. Here we show that vimentin, particularly under compressive load, promotes DNA repair competence. In contrast, vimentin-negative cells show impaired DNA damage sensing and downstream signaling, ultimately leading to decreased apoptosis and promoting cell survival under genotoxic stress at the expense of genomic stability. Using controlled cell compression together with genetic and pharmacological perturbations, we find that loss of vimentin in glioblastoma cells limits the expression and activity of core repair pathways because of induced nuclear mechanical compression. Relieving nuclear compression restores DNA damage accumulation and repair kinetics. Functionally, suppression of DNA damage responses enhances survival after clinically relevant DNA-damaging treatments, including temozolomide, X-Ray radiation and cell invasion through tight spaces. These findings invert the prevailing view that vimentin's contribution to tumour progression stems from enhanced migration and identify a mechanochemical vimentin-nucleus axis that tunes DNA damage responses to favor therapy tolerance and genome evolution.

Indexed as

DNA DamageVimentinApoptosisCell Line, TumorCell NucleusCell SurvivalDacarbazineDNA RepairHumansSignal TransductionTemozolomideDacarbazineTemozolomideVimentin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.